Hyloris Pharmaceuticals SA (EBR:HYL)

Market Cap	135.80M -25.4%
Revenue (ttm)	8.83M -9.5%
Net Income	-6.33M
EPS	-0.23
Shares Out	28.00M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	4,978
Average Volume	8,212
Open	5.260
Previous Close	5.280
Day's Range	4.850 - 5.320
52-Week Range	4.510 - 8.400
Beta	0.65
RSI	36.88
Earnings Date	Apr 30, 2026

About Hyloris Pharmaceuticals

Hyloris Pharmaceuticals SA engages in the research, development, and manufacture of pharmaceutical products to address medical needs. The company offers Maxigesic IV, a combination of paracetamol and ibuprofen used for post-operative pain, the opioid crisis, and acute pain; Podofilox Gel, an antimycotic drug for the treatment of external genital and perianal warts caused by various types of the human papilloma virus; and Sotalol IV to treat atrial fibrillation. It also develops Aspirin IV and HY-074 IV to reduce the risk of morbidity and mortal...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2012
• Employees: 50
• Stock Exchange: Euronext Brussels
• Ticker Symbol: HYL

Financial Performance

In 2025, Hyloris Pharmaceuticals's revenue was 8.83 million, a decrease of -9.50% compared to the previous year's 9.76 million. Losses were -6.33 million, -0.13% less than in 2024.